Quantifying Vaccine-Induced Neutralizing Antibodies in SARS-CoV-2 Variants

Summary

Automatic Translation

• العربية (Arabic)
• 中文 (Chinese)
• dansk (Danish)
• Nederlands (Dutch)
• français (French)
• Deutsch (German)
• עברית (Hebrew)
• हिंदी (Hindi)
• italiano (Italian)
• 日本語 (Japanese)
• 한국어 (Korean)
• norsk (Norwegian)
• português (Portugese)
• русский (Russian)
• español (Spanish)
• svenska (Swedish)
• Türkçe (Turkish)

This protocol describes the application of a novel hybrid alphavirus-SARS-CoV-2 pseudovirus (Ha-CoV-2) as a platform for rapid quantification of infectivity of SARS-CoV-2 variants and their sensitivity to neutralizing antibodies.